Αρχική World News Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for... World News Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD Από Ogkologos - 7 Νοεμβρίου, 2025 317 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health 23 Δεκεμβρίου, 2019 Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 9 Ιουλίου, 2020 Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer 24 Μαΐου, 2023 Bringing a Piece of Home to the Hospital 4 Απριλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Hamlet Drug, Modeled After Protein In Breast Milk, Kills Tumor Cells... Cómo solicitar Medicare cuando tiene cáncer News digest – targeted drug approval, microbubble ‘warheads’ and prostate cancer... What Are Multi-Cancer Early Detection Tests and How Might They Impact...